Acurx Pharmaceuticals (ACXP) vs FibroBiologics (FBLG)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
FibroBiologics is the larger company by market cap ($6.3 million vs $6.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACXP | FBLG |
|---|---|---|
| Share price | $1.04 | $0.705 |
| Market cap | $6.30M | $6.34M |
| 1-day change | +0.97% | -15.06% |
| EPS (TTM) | $-1.90 | $-2.51 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-7.97M | $-18.65M |
| 52-week high | $7.54 | $9.60 |
| 52-week low | $0.90 | $0.62 |
| Distance from 52-week high | -86.21% | -92.66% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +1534.62% | +1673.05% |
| Average volume | 97.29K | 160.05K |
| Shares outstanding | 6.06M | 8.99M |
| Employees | 4 | 15 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Acurx Pharmaceuticals
ACXP stock →Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections.
Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees
About FibroBiologics
FBLG stock →FibroBiologics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of fibroblast-based therapies for patients suffering from chronic diseases. The company's product pipeline includes CYWC628 which has completed pre-clinical trial for the treatment of wound healing; CYMS101 which has completed Phase 1 trial for the treatment of multiple sclerosis; CybroCell for the treatment of degenerative disc disease; and CYPS317 for the treatment of psoriasis.
Health Care · Biotechnology: Pharmaceutical Preparations · 15 employees
ACXP vs FBLG FAQ
Which is bigger, Acurx Pharmaceuticals or FibroBiologics?
FibroBiologics (FBLG) is larger, with a market capitalization of $6.34M compared with $6.30M for Acurx Pharmaceuticals (ACXP).
Are Acurx Pharmaceuticals and FibroBiologics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.